tiprankstipranks
Advertisement
Advertisement

CVKD Stock Latest News

Cadrenal Names Interim CFO, Realigns Board Structure
Company AnnouncementsCadrenal Names Interim CFO, Realigns Board Structure
10h ago
8K
CVKD
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
PremiumCompany Announcements
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
12d ago
8K
CVKD
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
PremiumThe Fly
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
12d ago
CVKD
Cadrenal Therapeutics to initiate CAD-1005 trial
PremiumThe Fly
Cadrenal Therapeutics to initiate CAD-1005 trial
15d ago
CVKD
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment
PremiumCompany Announcements
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment
26d ago
8K
CVKD
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
PremiumThe FlyCadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
2M ago
CVKD
Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial
Premium
Company Announcements
Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial
2M ago
8K
CVKD
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
Premium
The Fly
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
2M ago
CVKD
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
PremiumThe Fly
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
3M ago
CVKD
Cadrenal Therapeutics Inc trading halted, volatility trading pause
PremiumThe Fly
Cadrenal Therapeutics Inc trading halted, volatility trading pause
3M ago
CVKD
Cadrenal Therapeutics Inc trading resumes
PremiumThe Fly
Cadrenal Therapeutics Inc trading resumes
3M ago
CVKD
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
PremiumCompany Announcements
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
3M ago
8K
CVKD
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
PremiumCompany AnnouncementsFDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
3M ago
CVKD
Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
4M ago
CVKD
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
Premium
Company Announcements
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
4M ago
8K
CVKD
Cadrenal Therapeutics highlights research on 12-LOX inhibition
PremiumThe Fly
Cadrenal Therapeutics highlights research on 12-LOX inhibition
4M ago
CVKD
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
PremiumThe Fly
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
4M ago
CVKD
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005
PremiumCompany Announcements
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005
4M ago
8K
CVKD
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
PremiumThe Fly
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
4M ago
CVKD
Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution
PremiumThe FlyCadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution
6M ago
CVKD
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity
Premium
Company Announcements
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity
6M ago
8K
CVKD
Cadrenal Therapeutics Announces New Securities Purchase Agreement
Premium
Company Announcements
Cadrenal Therapeutics Announces New Securities Purchase Agreement
7M ago
8K
CVKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >